Fig. 1 · Structure

Documents & Downloads

Bedaquiline (TMC-207)

Cat. No. A12327 CAS 843663-66-1
TMC207 is a first-in-class diarylquinoline compound with a novel mechanism of action, the inhibition of bacterial ATP synthase, and potent activity against drug-sensitive and drug-resistant TB.

In Stock

Publications for Bedaquiline

24 publications citing this product

  1. Amrendra Kumar, .et al. , bioRxiv, 2026, Jan 6:2026.01.05.697836 PMID: 41542422
  2. Jiyun Park, .et al. , Antimicrob Agents Chemother, 2026, Feb 4;70(2):e0151125 PMID: 41416824
  3. Suzanna H Harrison, .et al. , Nat Commun, 2025, Nov 25;16(1):11018 PMID: 41290674
  4. Qinlong Yu, .et al. , Infect Drug Resist, 2025, Oct 4;18:5239-5247 PMID: 41069760
  5. Daniel J Pfau, .et al. , Autophagy Rep, 2025, 4(1):2473765 PMID: 40265045
  6. Nabila Ismail, .et al. , bioRxiv, 2025, March 11 PMID: 40161652
  7. Boatema Ofori-Anyinam, .et al. , Nat Commun, 2024, Nov 13;15(1):9792 PMID: 39537610
  8. Khomotso Mmakola, .et al. , Int J Mol Sci, 2024, Dec 4;25(23):13022 PMID: 39684733
  9. Asmita Sapkota, .et al. , Biomed Pharmacother, 2024, Oct:179:117313 PMID: 39167844
  10. Thanh Quang Nguyen, .et al. , Microbiol Spectr, 2023, Jun 15;11(3):e0063123 PMID: 37158736

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Bedaquiline inhibits mycobacterial ATP synthase. In M. phlei membrane vesicles, ATP synthesis was inhibited with a reported IC50 of 20–25 nM. An isolated c-ring structure placed bedaquiline at the proton-binding region, including interaction of its dimethylamino group with Glu65. These findings support c-ring engagement in a surrogate mycobacterial model. These surrogate experiments do not establish selectivity over human mitochondrial ATP synthase. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
Vero IC50 > 10 μg/mL Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay [PMID: 30792104]
Vero IC50 > 10 μg/mL Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay [PMID: 29107541]
Vero IC50 > 10 μg/mL Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay [PMID: 30803745]
Vero IC50 > 10 μg/mL Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay [PMID: 30891129]
Vero IC50 > 10 μM Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay [PMID: 29259747]
Vero IC50 4 μg/mL Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTS-PBS assay [PMID: 31810890]

Bedaquiline (TMC-207) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Bedaquiline (TMC-207) from 3 published references. In vitro models include Mycobacterium phlei inverted membrane vesicles (cell-free preparation); human MCF7 breast cancer cells, monolayer. In vivo models include MDA-MB-231 breast cancer xenografts on chick-embryo CAM.

Bedaquiline (TMC-207) In Vitro Studies

Bedaquiline reduced oxygen consumption and the ATP-production-associated Seahorse readout in MCF7 cells after 48 h at 1 or 10 µM. In hTERT-BJ1 fibroblasts, 10 µM for 48 h increased these readouts. The opposing responses limit generalization across cell types. [2]

ATP synthesis inhibition in mycobacterial membrane vesicles

Biochemical assay · Mycobacterium phlei inverted membrane vesicles (cell-free preparation) [1]

Bedaquiline inhibited ATP synthesis. CCCP, DCCD and omission of ADP served as negative controls; untreated vesicles synthesized ATP. The endpoint is biochemical ATP synthesis, not bacterial growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of ATP synthesisIC50 20–25 nM[1]
ATP synthesis at 0.1 µM BDQqualitative Completely abolished in reported trace[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–1 µM concentration-response; 0.1 µM in continuous trace
Exposure duration
10 min mixing before substrate addition; subsequent continuous monitoring
Method
Luciferin/luciferase ATP synthesis assay
Reported limits
Final vehicle percentage and replicate/error semantics for Figure 2 are not stated in the selected caption/method; no growth MIC adopted.
Methods and source locations

Compound reported in the paper: Bedaquiline (TMC-207); Compound label in the paper: BDQ

Named active-moiety evidence only; no salt conversion, product-lot equivalence or clinical efficacy inference.

Figure 2A–C and caption; Results: Inhibition of the M. phlei ATP synthase; Methods: continuous luciferin/luciferase ATP synthesis assay

Inhibition of ATP synthesis: Luminescence-based ATP synthesis concentration-response — Figure 2B–C; Results: Inhibition of the M. phlei ATP synthase

ATP synthesis at 0.1 µM BDQ: Continuous luminescence with untreated and negative controls — Figure 2A and caption

Structural localization at the c-ring proton-binding site

Biochemical assay · Purified M. phlei ATP synthase c9 rotor ring, BDQ-bound and apo crystals [1]

The BDQ dimethylamino group occupies the ion-binding region and interacts with Glu65. Bromine anomalous density supports ligand localization. This isolated-ring structure supports target engagement, while rotor-blocking behavior is a mechanistic interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ligand localization at c-ring ion-binding sitesstructural observation BDQ at the ion-binding region, with dimethylamino interaction at Glu65[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.35 mM added for cocrystallization
Method
X-ray crystallography with apo comparison and anomalous bromine signal
Reported limits
No product lot, isolated salt or analytical stereochemistry validation provided in the selected original text.
Methods and source locations

Compound reported in the paper: Bedaquiline (TMC-207); Compound label in the paper: BDQ

Named active-moiety evidence only; no salt conversion, product-lot equivalence or clinical efficacy inference.

Figure 4A–E and caption; Results: BDQ molecule specifically interacts with the c-ring; Methods: crystallization and structure determination

Ligand localization at c-ring ion-binding sites: Electron density/anomalous bromine localization and apo comparison — Figure 4C–E; Results: BDQ molecule specifically interacts with the c-ring

Metabolic response in MCF7 breast cancer cells

Cell-based study · Human MCF7 breast cancer cells, monolayer [2]

Bedaquiline reduced basal and maximal oxygen consumption and the Seahorse ATP-production-associated readout relative to DMSO controls. This metabolic measurement does not establish direct binding to a particular ATP synthase subunit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal/maximal respiration and ATP-production-associated Seahorse readoutdirection Decreased relative to control[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 and 10 µM
Exposure duration
48 h
Method
Seahorse XFe-96 extracellular flux; protein normalization
Vehicle
DMSO control
Reported limits
Final DMSO percentage not specified in the selected method. Figure 2 calls the derived readout ATP levels, while the panel says ATP production; it is not an independent absolute ATP concentration.
Methods and source locations

Compound reported in the paper: Bedaquiline (TMC-207); Compound label in the paper: Bedaquiline

Named active-moiety evidence only; no salt conversion, product-lot equivalence or clinical efficacy inference.

Figure 2A–D and caption; Results: Metabolic profiling of MCF7; Methods: Materials and Seahorse XFe-96 analysis

Basal/maximal respiration and ATP-production-associated Seahorse readout: Protein-normalized extracellular flux; quintuplicate wells, three independent experiments per Methods; caption describes three independent experiments — Figure 2A–D; Seahorse methods

Opposite metabolic response in fibroblasts

Cell-based study · Immortalized human hTERT-BJ1 fibroblasts [2]

At 10 µM, bedaquiline increased basal and maximal respiration and the ATP-production-associated Seahorse readout. These fibroblast results limit generalization of the inhibitory response observed in MCF7 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal/maximal respiration and ATP-production-associated Seahorse readoutdirection Increased relative to control[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
48 h
Method
Seahorse XFe-96 extracellular flux; protein normalization
Vehicle
DMSO control
Reported limits
Final DMSO percentage not specified. Figure 5 caption mistakenly names MCF7 in its first sentence; Results, plot labels and section identify hTERT-BJ1. Immortalized fibroblasts do not establish clinical tolerability.
Methods and source locations

Compound reported in the paper: Bedaquiline (TMC-207); Compound label in the paper: Bedaquiline

Named active-moiety evidence only; no salt conversion, product-lot equivalence or clinical efficacy inference.

Figure 5A–D and caption; Results: Metabolic profiling of normal human fibroblasts; Methods: Materials and Seahorse analysis

Basal/maximal respiration and ATP-production-associated Seahorse readout: Protein-normalized extracellular flux; three independent experiments, quintuplicate wells per shared Methods — Figure 5A–D; Results: fibroblast metabolic profiling; Seahorse methods

Bedaquiline (TMC-207) In Vivo Studies

In a chick-embryo CAM model of MDA-MB-231 dissemination, daily bedaquiline treatment for eight days reduced lower-CAM human Alu signal, with a maximum reported inhibition of 84% at 120 µM. Primary tumor weight did not change significantly, and embryo survival did not show added toxicity versus vehicle. These embryonic-model findings do not establish human efficacy or systemic safety. [3]

Metastasis and tumor-growth outcomes in chick embryos

Animal study · MDA-MB-231 breast cancer xenografts on chick-embryo CAM [3]

Bedaquiline reduced the dissemination readout while leaving tumor weight without a statistically significant change. Embryo survival did not show added toxicity under these conditions. This single embryonic model supports neither human anticancer efficacy nor systemic safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Human Alu qPCR signal in lower CAMmaximum reported inhibition 84% at 120 µM; N ≥ 7 per group[3]
Primary tumor weightstatistical result No significant effect; N ≥ 14 per group[3]

Conditions shared by the study groups

Frequency
Daily
Treatment course
8 days, E10–E18
Vehicle
1% DMSO in PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bedaquiline concentration groups
60, 90 and 120 µM (administered solution concentrations; no mass-per-egg dose inferred)
Vehicle aloneDose-dependent reduction of lower-CAM human Alu signal, maximum reported inhibition 84% at 120 µM (N ≥ 7 per group). Tumor weight was not significantly changed (N ≥ 14 per group); embryo survival was not detectably worsened versus vehicle (N ≥ 14 per group).[3]
Bedaquiline concentration groups
Model: MDA-MB-231 xenografts on White Leghorn chick-embryo chorioallantoic membrane
Reported limits: Administration route and volume are not specified in the read main-text methods/caption. Salt, supplier and lot are not specified in the read Reagents section.
Methods and source locations

Compound reported in the paper: Bedaquiline (TMC-207); Compound label in the paper: Bedaquiline

Named active-moiety evidence only; no salt conversion, product-lot equivalence or clinical efficacy inference.

Figure 7K–O and caption; Methods: CAM xenograft assays; Results: targeting ATP5F1C with bedaquiline

Human Alu qPCR signal in lower CAM: Vehicle-controlled CAM xenograft comparison; one-way ANOVA with Dunnett post-test — Figure 7O and caption

Primary tumor weight: Tumor weighing; one-way ANOVA with Dunnett post-test — Figure 7N and caption

Bedaquiline concentration groups · Figure 7K–O and caption; Methods: CAM xenograft assays; Results: targeting ATP5F1C with bedaquiline

Specifications

Manufacturer Adooq Bioscience
CAS Number 843663-66-1
Formula C32H31BrN2O2
Molecular Weight 555.5
Synonyms TMC-207
SMILES
CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 11 mg/mL (19.8 mM)
Water Insoluble
Ethanol 3 mg/mL (5.4 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bedaquiline (TMC-207) Research References

  1. [1] Preiss L, Langer JD, Yildiz Ö, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Science advances (2015). PMID: 26601184 DOI: 10.1126/sciadv.1500106 Source material
  2. [2] Fiorillo M, Lamb R, Tanowitz HB, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (2016). PMID: 27344270 DOI: 10.18632/aging.100983 Source material
  3. [3] Fiorillo M, Scatena C, Naccarato AG, et al. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell death and differentiation (2021). PMID: 33986463 DOI: 10.1038/s41418-021-00788-x Source material

Publications

24 publications citing this product

  1. Amrendra Kumar, .et al. , bioRxiv, 2026, Jan 6:2026.01.05.697836 PMID: 41542422
  2. Jiyun Park, .et al. , Antimicrob Agents Chemother, 2026, Feb 4;70(2):e0151125 PMID: 41416824
  3. Suzanna H Harrison, .et al. , Nat Commun, 2025, Nov 25;16(1):11018 PMID: 41290674
  4. Qinlong Yu, .et al. , Infect Drug Resist, 2025, Oct 4;18:5239-5247 PMID: 41069760
  5. Daniel J Pfau, .et al. , Autophagy Rep, 2025, 4(1):2473765 PMID: 40265045
  6. Nabila Ismail, .et al. , bioRxiv, 2025, March 11 PMID: 40161652
  7. Boatema Ofori-Anyinam, .et al. , Nat Commun, 2024, Nov 13;15(1):9792 PMID: 39537610
  8. Khomotso Mmakola, .et al. , Int J Mol Sci, 2024, Dec 4;25(23):13022 PMID: 39684733
  9. Asmita Sapkota, .et al. , Biomed Pharmacother, 2024, Oct:179:117313 PMID: 39167844
  10. Thanh Quang Nguyen, .et al. , Microbiol Spectr, 2023, Jun 15;11(3):e0063123 PMID: 37158736
  11. Rubeshan Perumal, .et al. , Infect Drug Resist, 2023, May 9;16:2849-2859 PMID: 37193296
  12. Christian C Otum, .et al. , Sci Rep, 2023, Jun 6;13(1):9212 PMID: 37280265
  13. Thanh Quang Nguyen, .et al. , Antimicrob Agents Chemother, 2022, Dec 20;66(12):e0044822 PMID: 36321819
  14. Jinsheng Cui, .et al. , Mar Drugs, 2022, Jun 16;20(6):400 PMID: 35736203
  15. Bettina Schulthess, .et al. , Antimicrob Agents Chemother, 2022, May 17;66(5) PMID: 35420492
  16. Puyskens A, .et al. , Cell Host Microbe, 2019, Dec 23. pii: S1931-3128(19)30634-1 PMID: 31901518
  17. Belosludtsev KN, .et al. , Biochim Biophys Acta Biomembr, 2019, Jan;1861(1):288-297 PMID: 29920239
  18. Meikle V, .et al. , Antimicrob Agents Chemother, 2018, Nov 12. pii: AAC.01846-18 PMID: 30420480
  19. Belosludtsev KN, .et al. , Chem Biol Interact, 2018, Nov 26;299:8-14 PMID: 30496736
  20. Wu X, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):267-272 PMID: 29107691
  21. Jichan Jang, .et al. , Antimicrob Agents Chemother, 2017, Jul; 61(7): e02637-16 PMID: 28416541
  22. Marco Fiorillo, .et al. , Aging (Albany NY), 2016, Aug; 8(8): 1593-1606 PMID: 27344270
  23. Alvaro A. Ordonez, .et al. , Antimicrob Agents Chemother, 2015, Jan; 59(1): 642-649 PMID: 25403669
  24. Ke Liu, .et al. , Drug Metab Dispos, 2014, May; 42(5): 863-866 PMID: 24513655

Showing 10 of 24 publications

Added to your cart

View Cart Checkout
Loading...